Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs W W Grainger Inc (GWW) Price & Performance

Amphastar Pharmaceuticals IncTrade
W W Grainger IncTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs W W Grainger Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while W W Grainger Inc trades at $1,300.82 (market cap $61.11B). The key difference: W W Grainger Inc is far larger — about 70.7× Amphastar Pharmaceuticals Inc's market cap, and W W Grainger Inc pays a 0.77% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMPHGWW
Market Cap
$863.95M$61.11B
Sector
HealthTechnology
52-Week High
$30.81$1.40K
52-Week Low
$16.87$918.18
Enterprise Value
$1.26B$63.32B
Dividend Yield
0.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

W W Grainger Inc

GWW trades at $1,277.55, down 0.39% on the day, amid a bearish technical signal. The stock has shown strong fundamental performance with Q2 2026 EPS beating estimates at $12.01 and revenue growth to $5.0 billion, leading to a raised full-year outlook. Analyst consensus is a Buy with a $1,310 price target, though technical indicators suggest near-term pressure with support at $1,270 and resistance at $1,290.

The outlook for GWW is positive based on earnings momentum and margin expansion, but risks include macroeconomic sensitivity and competitive pressures. The stock's high P/E of 33.07 indicates premium valuation, requiring sustained growth to justify current levels. Institutional sentiment remains cautious with a Hold-heavy rating distribution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About W W Grainger Inc

Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.

Read more on GWW